Leo Pharma elaborates on 2030 strategy after new capital injection
Backed by Nordic Capital, Leo Pharma is now free to power ahead with the strategy that will ideally lead to Leo Pharma becoming a global, leading player in medical dermatology by 2030, according to CEO Catherine Mazzacco.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The reason why Leo Pharma is gaining new capital through divesting parts of its ownership is very specific.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma struggles with lawsuit in the US
For subscribers
